Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System
- 주제(키워드) economic evaluation , pharmaceutical , policy evaluation , reimbursement , South Korea
- 주제(기타) Pharmacology & Pharmacy
- 설명문(일반) [Gong, Ji Ryoun] Hlth Insurance Review & Assessment Serv, Wonju, South Korea; [Gong, Ji Ryoun; Lim, Kyung-Min; Bae, SeungJin] Ewha Womans Univ, Coll Pharm, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Lee, Donghwan] Ewha Womans Univ, Dept Stat, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 ELSEVIER
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000174591
- 본문언어 영어
- Published As http://dx.doi.org/10.1016/j.clinthera.2020.05.006
- PubMed https://pubmed.ncbi.nlm.nih.gov/32487429
초록/요약
Purpose: The South Korean government in 2014 introduced various policies to enhance accessibility of pharmaceuticals. This study sought to examine whether positive reimbursement recommendations of pharmaceuticals have increased since 2014. Methods: Industry submissions evaluated from January 2007 to December 2018 were identified, and characteristics relevant to reimbursement recommendations were extracted. Logistic regression analyses with robust SEs were used to quantify the likelihood of positive recommendations for pharmaceuticals, after controlling for relevant factors influencing the recommendations. Findings: During the study period, 355 (72.9%) of 487 submissions were positively recommended; the drugs evaluated after 2014 (77.8%) were significantly more likely to receive positive reimbursement recommendations than the drugs evaluated before 2014 (69.5%). In the multivariable logistic regression analysis, several factors (labeled a noncancer drug, priced less than alternatives, considered clinically superior, and having budget impact >10 billion South Korean won) were significantly associated with positive recommendations (P < 0.05). When considering interaction effects between evaluation year and other variables, only the interaction between comparative clinical benefit and evaluation year was significant. Specifically, clinically noninferior drugs evaluated after 2014 had 2.85 times the odds of receiving positive recommendations compared with the clinically noninferior drugs evaluated earlier. (C) 2020 The Authors. Published by Elsevier Inc.
more